Noureen Akbar
Family Medicine · Orlando, FLNPI 1306138623
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Novo Nordisk at 25.8% of the total. Reporting peaked in 2019 at $966 and has fallen 88.5% since, to $111 in 2025.
Across 82 payments — averaging $17.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$365
- Boehringer Ingelheim$162
- Sanofi-aventis U.S. LLC$133
- AstraZeneca$120
- Teva Pharmaceuticals USA, Inc.$116
- Astellas Pharma US Inc$75
- plus $443 from 13 others
What the payments were for
- Food & beverage$1,414100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 23 | $365 |
| Boehringer Ingelheim | 4 | $162 |
| Sanofi-aventis U.S. LLC | 8 | $133 |
| AstraZeneca | 7 | $120 |
| Teva Pharmaceuticals USA, Inc. | 7 | $116 |
| Astellas Pharma US Inc | 4 | $75 |
| GSK | 4 | $62 |
| Merck | 4 | $51 |
| Johnson & Johnson | 3 | $44 |
| Gilead | 2 | $40 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $37 |
| Amgen | 2 | $36 |
| Lilly USA, LLC | 3 | $34 |
| Phadia US Inc. | 2 | $33 |
| Amarin Pharma, Inc. | 2 | $31 |
| Arbor Pharmaceuticals, Inc. | 2 | $25 |
| Novartis | 1 | $20 |
| Pfizer | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $12 |
How this compares
$1,414 in reported general payments places this provider in the 70th percentile of 7,282 family medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 50 | $59,069 |
| EliquisApixaban | 49 | $57,399 |
| OzempicSemaglutide | 29 | $38,245 |
| JanuviaSitagliptin Phosphate | 20 | $29,477 |
| JardianceEmpagliflozin | 15 | $24,120 |
| Spiriva HandihalerTiotropium Bromide | 11 | $16,134 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 78 | $11,163 |
| LinzessLinaclotide | 13 | $10,880 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $5,712 |
| Novolin 70-30 FlexpenInsulin Nph Hum/Reg Insulin Hm | 13 | $4,930 |
| DuleraMometasone/Formoterol | 11 | $4,239 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 16 | $3,734 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 92 | $3,497 |
| Wixela InhubFluticasone Propion/Salmeterol | 13 | $2,344 |
| Diclofenac Sodium | 131 | $2,237 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $120 | $59,06950 claims |
| PfizerEliquis | $17 | $57,39949 claims |
| Novo NordiskOzempic | $365 | $38,24529 claims |
| MerckJanuvia, Dulera | $51 | $33,71631 claims |
| Boehringer IngelheimJardiance | $162 | $24,12015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Orlando
- Richard LappOrlando$702K
- Asim RahmanOrlando$124K
- Arilda MargjoniOrlando$71K
- Rafael PineroOrlando$61K
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
- Giovana Rene CrooksBoca Raton$407K
- Edward BraunSt Petersburg$364K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.